Clinical efficacy of Lianhua Qingwen integrated with Western medicine on COVID-19 by Meta-analysis
10.7501/j.issn.0253-2670.2020.14.021
- VernacularTitle: 连花清瘟联合西医治疗新型冠状病毒肺炎临床疗效的Meta分析
- Author:
Shu-Xia WANG
1
Author Information
1. School of Public Health, Gansu University of Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Efficacy;
Integrated Chinese and western medicine;
Lianhua Qingwen;
Meta-analysis;
Novel coronavirus disease (COVID-19)
- From:
Chinese Traditional and Herbal Drugs
2020;51(14):3763-3769
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To systematically evaluate the efficacy of Lianhua Qingwen (LQC) on COVID-19, and provide evidence for the formulation and optimization of clinical therapy on COVID-19. Methods: Six databases (PubMed, Cochrane Library, Wanfang, Weipu, CBM and CNKI) were searched up to May 27, 2020. The Cochrane collaborative bias risk tool was used for risk evaluation and quality assessment; Meta-analysis was carried out by Stata 15 software. Begg's test was used for publication bias. Results: Seven clinical trials were included with 665 COVID-19 patients. Compared with Western medicine alone, integrated Lianhua Qingwen significantly improved the effective rate of clinical symptoms [RR = 1.24, 95% CI (1.12, 1.38), P < 0.05] of COVID-19, increased CT improvement [RR = 1.14, 95% CI (1.02, 1.28), P < 0.05] and reduced the proportion of progressing into sever clinical level [RR = 0.48, 95% CI (0.31, 0.72), P < 0.05]; In addition, integrated Lianhua Qingwen could effectively shorten the duration of fever [SMD = -0.87, 95% CI (-1.22,-0.52), P < 0.05], time of clinical symptoms disappearance [SMD = -1.19, 95% CI (-1.56, -0.82), P < 0.05] and hospital stay [SMD = -0.61, 95% CI (-0.91, -0.30), P < 0.05]. Conclusion: Lianhua Qingwen could be used as adaptive and complementary medicine to improve clinical symptoms and CT for COVID-19.
